type 1 diabetes Archives -

Shares in Provention Bio cratered last July when the FDA turned down its marketing application for type 1

FDA sets August decision date for Provention’s type 1 diabetes drug

https://pharmaphorum.com/news/fda-sets-august-decision-date-for-proventions-type-1-diabetes-drug/

Vertex builds in gene editing yet again, with $1.2bn Arbor deal

Phil Taylor Arbor Biotechnologies, beta thalassaemia, CRISPR/Cas9, gene editing, sickle cell disease, type 1 diabetes, Vertex Pharma 0 Comment

Vertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of

Vertex builds in gene editing yet again, with $1.2bn Arbor deal

https://pharmaphorum.com/news/vertex-builds-in-gene-editing-yet-again-with-1-2bn-arbor-deal/

Market Access/ News/ News

FDA rejects Provention’s type 1 diabetes drug teplizumab

Phil Taylor Diabetes, fda, metabolic disease, Provention Bio, teplizumab, type 1 diabetes 0 Comment

The FDA indicated something was not well with Provention Bio’s filing for type 1 diabetes therapy teplizumab in

FDA rejects Provention’s type 1 diabetes drug teplizumab

https://pharmaphorum.com/news/fda-rejects-proventions-type-1-diabetes-drug-teplizumab/

Market Access/ News/ News

Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEO

Phil Taylor artificial pancreas, continuous glucose monitoring, insulin, NHS England, NICE, Simon Stevens, type 1 diabetes 0 Comment

NHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot

Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEO

https://pharmaphorum.com/news/artificial-pancreas-will-be-piloted-in-1000-diabetics-says-nhs-ceo/

Market Access/ News/ News

Provention faces delay in FDA review of diabetes prevention antibody

Phil Taylor antibody, fda, metabolic disease, Provention Bio, teplizumab, type 1 diabetes 0 Comment

The FDA says it has uncovered “deficiencies” in the marketing application for Provention Bio’s much-anticipated drug teplizumab for

Provention faces delay in FDA review of diabetes prevention antibody

https://pharmaphorum.com/news/provention-faces-delay-in-fda-review-of-diabetes-prevention-antibody/

News/ News/ R&D

FDA fast tracks type 1 diabetes cell therapy from Vertex

Phil Taylor cell therapy, fda, FDA fast track, Regenerative medicine, type 1 diabetes, Vertex Pharma 0 Comment

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and

FDA fast tracks type 1 diabetes cell therapy from Vertex

https://pharmaphorum.com/news/vertex-claims-fda-fast-track-status-for-diabetes-cell-therapy/

Digital/ News/ News

FDA approves Tandem’s connected insulin controller

Phil Taylor artificial pancreas, insulin, type 1 diabetes 0 Comment

Tandem Diabetes Care has claimed approval in the US for a new software system that can be used

FDA approves Tandem’s connected insulin controller

https://pharmaphorum.com/news/fda-approves-tandems-connected-insulin-controller/

News/ News/ R&D

Sanofi builds case for Toujeo in younger type 1 diabetics

Phil Taylor Diabetes, insulin, Lantus, Sanofi, Toujeo, type 1 diabetes 0 Comment

Sanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but

Sanofi builds case for Toujeo in younger type 1 diabetics

https://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/

News/ News/ R&D/ Top stories

Astellas cuts $795m deal with Pandion for type 1 diabetes drugs

Phil Taylor Astellas, licensing, Pandion Therapeutics, type 1 diabetes 0 Comment

Astellas Pharma is boosting its early-stage pipeline with a $45 million upfront deal to license bispecific antibodies from

Astellas cuts $795m deal with Pandion for type 1 diabetes drugs

https://pharmaphorum.com/news/astellas-biotech-deal-pandion-diabetes/

Trending

type 1 diabetes

Login